Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies.

"Conflict of Interests STBH, DT, ES, RWMP, JM, AL, RB, WL none. CW received grant support from Falk Benelux and Pfizer; received speaker fees from AbbVie, Takeda, Ferring, Dr. Falk Pharma, Hospira, and Pfizer; and served as a consultant for AbbVie, MSD, Takeda, Celgene, Mundipharma, and Janssen. MJ has received education funding from Pfizer, Takeda, Janssen, MSD, Ferring, Abbvie, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, and Norgine. GB has received lecture fees from Abbvie, Ferring, MSD, Takeda, and Pfizer, and consultant fees from Takeda and Janssen. TM has received speaker’s honoraria from MSD, AbbVie, Egis, Goodwill Pharma, Takeda, Pfizer, and Teva. JS has served as national coordinator on studies from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Eli Lilly, and Roche/Genentech, and received an unrestricted research grant from Takeda. AA has received consulting fees from Abbvie, Hospira, Takeda, Gilead, and Biocodex as well as lecture fees and travel accommodations from Abbvie, Janssen, Biocodex, Hospira, Ferring, Takeda, and MSD. AA also received advisory board fees from Gilead, Takeda, and AbbvieX. GDH has served as advisor for Abbvie, Ablynx, Alimentiv, Amgen, AM Pharma, Biogen, Bristol Meiers Squibb, Boerhinger Ingelheim, Celgene/Receptos, Celltrion, Cosmo, Covidien/Medtronics, Ferring, DrFALK Pharma, Eli Lilly, Engene, Galapagos, Genentech/Roche, Gilead, Glaxo Smith Kline, Immunic, Johnson and Johnson, Lamepro, Lument, Mitsubishi Pharma, Merck Sharp Dome, Mundipharma, Nextbiotics, Novonordisk, Otsuka, Pfizer, Polpharm, Prometheus laboratories/Nestle, Procise diagnostics, Protagonist, Salix, Samsung Bioepis, Sandoz, Setpoint, Shire, Takeda, Tigenix, Tillotts, Topivert, Versant, and Vifor; and received speaker fees from Abbvie, Biogen, Ferring, Johnson and Johnson, Merck Sharp Dome, Mundipharma, Norgine, Pfizer, Samsung Bioepis, Shire, Takeda, Tillotts, and Vifor. PR has received consultancy fees from Abbvie, Amgen, and Janssen. LG has received consultancies and/or speaker fees from AbbVie, Janssen, MSD, Mundipharma, Takeda, Vifor Pharma, and Zambon. LPB has received grant support, consulting fees, lecture fees, and advisory board fees from AbbVie, Takeda, and MSD, consulting fees, lecture fees, and advisory board fees from Janssen, Ferring, Tillots, Celltrion, Pfizer, and Roche, consulting fees and advisory board fees from Genentech, Pharmacosmos, Sandoz, Celgene, Allergan, Arena, Gilead, and Amgen, consulting fees from Boehringer Ingelheim, Index Pharmaceuticals, and Alma, consulting fees and lecture fees from Biogen and Samsung Bioepis, advisory board fees from Sterna, Nestle, and Enterome, lecture fees from Hikma, and holding stock options in CT-SCOUT. JPG has served as speaker, consultant, and advisory member for or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos, Lilly, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine, and Vifor Pharma. AV has participated in advisory board and/or received financial compensation from the following companies: Janssen, Takeda, Abbvie, and Tramedico."

"Funding No funding has been received for this specific study."